Ips (4390) · RiskRestated
Dependence on the joint venture relationship with I SUPPORT and medical technology
First written in FY2018. 1 of 2 entries say "Restated". Latest entry: FY2019.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Risk of unsuccessful R&D and business partnership development and changes in relationshipsA theme 56 companies write about · 59 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2023: 4 of 18 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 56 companies compared. The sentences above are computed from all 56.Full recordFilings, disclosures and news, newest first
- FY2019RestatedAnnual report
「SLAC outsources the selection of medical equipment and physician training, among other matters, to I SUPPORT, which plays an important role in the operation of the Group's medical and aesthetic businesses.」
The disclosure reiterates the 50% joint venture relationship with I SUPPORT and dependence on medical equipment selection and physician training. - FY2018First statedAnnual report
「The Company jointly invested in SLAC, its overseas subsidiary, with I SUPPORT, a Singaporean company engaged in the sale of medical equipment and investments in Singaporean medical corporations including SHINAGAWA EYE Centre. The Company's voting rights ownership ratio is 50%.」
The Company outsources medical equipment selection and physician training to I SUPPORT, indicating a business continuity risk if the joint venture relationship is dissolved.